Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

An 11-game Sunday NFL DFS 'main slate' schedule brings a loaded NFL DFS player pool in Week 14. Joe Burrow, Bijan Robinson, Derrick Henry, Davante Adams and Brock Bowers are just some of the stars to ...

Four games over the course of Thanksgiving Day and Black Friday will limit the NFL DFS main slate on FanDuel and DraftKings, but there are still plenty of big names to consider on Sunday. Justin ...

So, you’re looking to get better at coding with Python, and maybe you’ve heard about LeetCode. It’s a pretty popular place to practice coding problems, especially if you’re aiming for tech jobs.

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

DFS picks for Friday's 8-game slate in the NBA. Joe Williams, FantasyPros.com Jaren Jackson Jr. has made at least 50% of his field goal attempts in four out of five games this season. Happy Halloween.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

DFS picks for Wednesday's 10-game slate in the NBA. Nicholas Rodriguez, FantasyPros.com Ja Morant is an affordable, high-upside option with a favorable matchup against the Suns tonight in DFS.

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...